Lima PB, Dias JAF, Cassiano D, et al. - In this quasi‐randomized, multicenter, evaluator‐blinded clinical trial, researchers sought to evaluate the effectiveness and safety of topical 5% cysteamine vs 4% hydroquinone in the treatment of facial melasma in women. This investigation was carried out on 40 women with facial melasma who were submitted to the nightly application of 5% cysteamine (CYS) or 4% hydroquinone (HQ) on hyperpigmented areas for 120 days. Participants were evaluated at the inclusion and after 60 and 120 days of treatment for mMASI, MELASQoL, and the difference in colorimetric luminosity between melasma and the adjacent unaffected skin. Data reported that the mean reduction of the mMASI scores was 24% for CYS and 41% for HQ at 60 days, and 38% for CYS and 53% for HQ at 120 days. Despite its inferior performance to hydroquinone in decreasing mMASI and MELASQoL in the treatment of melasma, cysteamine proved to be safe, well‐tolerated, and effective.